New Computational Tools Developed by Mount Sinai Scientists Yield Superior Genome Analysis Results
Scientists from the Icahn School of Medicine at Mount Sinai have developed and publicly released new data analysis software that could help genomics researchers identify genetic drivers of disease with greater efficiency and accuracy. These tools were published yesterday in PLoS Computational Biology and on November 25th in Scientific Reports, a Nature publication.
MEGENA (for Multiscale Embedded Gene Co-expression Network Analysis) projects gene expression data onto a three dimensional sphere, allowing scientists to study hierarchical organization patterns in complex networks that are characteristic of diseases such as cancer, obesity, and Alzheimer’s. Tested on data from The Cancer Genome Atlas (TCGA), MEGENA identified novel regulatory targets in breast and lung cancers, outperforming other co-expression analysis methods.
The second tool, SuperExactTest, establishes the very first theoretical framework for assessing the statistical significance of multi-set intersections and enables users to compare very large sets of data, such as gene sets produced from genome-wide association studies (GWAS) and differential expression analysis. Scientists ran SuperExactTest on existing TCGA and GWAS data, identifying a core set of cancer genes and detecting related patterns among complex diseases. Both tools come from the Multiscale Network Modeling Laboratory led by Bin Zhang, PhD, Associate Professor in the Department of Genetics and Genomic Sciences.
“These tools fill important and unmet needs in genomics,” said Dr. Zhang, the senior author of the two papers. “MEGENA will help scientists flesh out novel pathways and key targets in complex diseases, while SuperExactTest will provide a clearer understanding of the genome by comparing a large number of gene signatures.”
“Our team is dedicated to crafting high-performance analysis tools and to sharing those resources with the broader genomics community to help us all generate the best possible results,” said Eric Schadt, PhD, the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai, and Founding Director of the Icahn Institute for Genomics and Multiscale Biology. “These new tools demonstrate thoughtful and creative solutions to computational challenges faced by scientists around the world, and I look forward to seeing what the community will accomplish with them.”
MEGENA and SuperExactTest are available as R packages at Dr. Zhang’s website (http://research.mssm.edu/multiscalenetwork/Resources.html) and CRAN (the Comprehensive R Archive Network), a repository of open-source software (https://cran.r-project.org/).
Won-Min Song and Bin Zhang. Multiscale Embedded Gene Co-expression Network Analysis. PLoS Computational Biology 11(11): e1004574. doi:10.1371/journal.pcbi.1004574 (http://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004574)
Minghui Wang, Yongzhong Zhao, and Bin Zhang. Efficient Test and Visualization of Multi-Set Intersections. Scientific Reports 5:16923. doi: 10.1038/srep16923 (http://www.nature.com/articles/srep16923)
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, over 400 outpatient practices, nearly 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,300 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is one of three medical schools that have earned distinction by multiple indicators: It is consistently ranked in the top 20 by U.S. News & World Report's "Best Medical Schools," aligned with a U.S. News & World Report "Honor Roll" Hospital, and top 20 in the nation for National Institutes of Health funding and top 5 in the nation for numerous basic and clinical research areas. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.